Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes

Figures & data

Table I. Clinical characteristics and age according to randomization group.

	Randomized to prostatectomy	Randomized to irradiation
T-stadium	n = 45 n (%)	n = 44 n (%)
T1	18 (40)	17 (39)
T2	17 (38)	16 (36)
T3	4 (9)	3 (7)
Unknown	6 (13)	8 (18)
Bone scan
Performed	27 (60)	28 (64)
Not performed	10 (22)	8 (18)
Unknown	8 (18)	8 (18)
Age
Median	64 years	66 years

Table II. Mean scores and standard deviations (SD) for the EORTC QLQ-C33 subscales and single items at three points of assessment according to randomization arm.

Variable	Randomization arm	Assessment points
		Randomization Mean (SD)	12 months Mean (SD)	24 months Mean (SD)
Physical functioning^1	Irradiation (n = 25)	95 (13)	94 (14)	94 (17)
	Prostatectomy (n = 33)	97 (11)	96 (9)	96 (12)
Role functioning^1	Irradiation (n = 26)	96 (14)	96 (14)	96 (14)
	Prostatectomy (n = 33)	92 (25)	94 (24)	97 (17)
Emotional functioning^1 p = 0.0005	Irradiation (n = 25)	78 (19)	86 (19)	87 (17)
	Prostatectomy (n = 33)	81 (21)	89 (15)	88 (16)
Cognitive functioning^1	Irradiation (n = 25)	89 (16)	88 (16)	88 (18)
	Prostatectomy (n = 31)	88 (12)	89 (10)	87 (13)
Social functioning^1 p = 0.0051	Irradiation (n = 26)	92 (13)	83 (21)	83 (24)
	Prostatectomy (n = 33)	92 (20)	82 (20)	90 (20)
Global quality of life^1	Irradiation (n = 24)	80 (18)	76 (22)	75 (20)
	Prostatectomy (n = 31)	82 (20)	77 (16)	77 (21)
Fatigue^2	Irradiation (n = 25)	11 (18)	14 (17)	12 (14)
	Prostatectomy (n = 32)	14 (18)	16 (15)	13 (16)
Pain^2	Irradiation (n = 26)	10 (16)	15 (18)	14 (24)
	Prostatectomy (n = 33)	7 (13)	10 (18)	8 (14)
Insomnia^2	Irradiation (n = 25)	13 (26)	12 (23)	8 (14)
	Prostatectomy (n = 33)	7 (14)	17 (24)	9 (15)
Constipation^2	Irradiation (n = 26)	4 (11)	5 (20)	3 (9)
	Prostatectomy (n = 33)	1 (6)	4 (14)	3 (10)
Diarrhea^2	Irradiation (n = 26)	6 (16)	14 (23)	9 (15)
	Prostatectomy (n = 33)	2 (8)	5 (12)	3 (10)
Financial difficulties^2 p = 0.0011	Irradiation (n = 26)	10 (16)	23 (31)	22 (31)
	Prostatectomy (n = 33)	8 (20)	24 (29)	11 (23)

¹Range 0–100, high values indicate high levels of functioning and quality of life; ²Range 0–100, high levels indicate pronounced symptom and problems.

Results which are marked as bold are statistically significant.

Table III. Frequencies of prostate cancer-specific problems, patients-reported response categories according to randomization group at three points of assessment.

Assessments	Randomization		12 months		4 months
	RT%	RP%	RT%	RP%	RT%	RP%
Urinary:
*Urgency
1	47	58	54	59	39	58
2	37	42	32	26	32	21
3	13	0	11	10	26	18
4	3	0	3	5	3	3
*Incontinence
p = 0.0011
1	76	83	76	46	61	45
2	17	14	19	41	29	39
3	7	0	5	5	5	11
4	0	3	0	8	5	5
Bowel:
*Incontinence
1	93	92	81	90	76	92
2	7	8	14	10	24	8
3	0	0	5	0	0	0
4	0	0	0	0	0	0
*Blood
1	90	10	89	92	79	94
2	10	0	8	8	15	3
3	0	0	3	0	3	3
4	0	0	0	0	3	0
General:
*Hot flushes
1	87	78	65	65	79	71
2	10	14	27	18	16	21
3	0	8	5	8	5	5
4	3	0	3	5	0	3
Sexual:
#Erectile problems
P ≤ 0.0001
1	21	31	5	3	3	5
2	32	36	19	5	11	5
3	32	22	19	11	27	16
4	15	11	57	81	59	74
#Sexual interest
p ≤ 0.0001
1	32	39	19	15	21	21
2	32	33	22	18	10	13
3	21	25	24	26	32	37
4	15	3	35	41	37	29

Response categories: 1 = Not at all; 2 = Little; 3 = Quite a bit; 4 = Very much. *30–38 patients (RT), 36–39 patients (RP); ^#28–37 patients (RT), 36–38 patients (RP).

Figure 1. Cumulative probability of prostate-specific survival in RP, radical prostatectomy group compared to RT, radiotherapy group.